SIGA Technologies, Inc. (SIGA) Analyse boursière

Présentation de l'entreprise

SIGA Technologies, Inc. operates within the healthcare sector, specifically functioning as a drug manufacturer in the specialty and generic pharmaceutical industry. The company focuses on the health security market in the United States, with its primary commercial activity centered on the development and commercialization of TPOXX, an antiviral medication designed for the treatment of human smallpox disease caused by the variola virus. Incorporated in 1995, this commercial-stage pharmaceutical entity maintains a workforce of 49 employees while holding a total market capitalization of $328.13 million. The company reported trailing twelve-month revenue of $94.57 million, a figure that, when combined with its employee count and market valuation, indicates a niche position focused on high-value, specialized therapeutic areas rather than mass-market pharmaceutical volume.

Santé financière

SIGA Technologies, Inc. generated revenue of $94.57 million over the trailing twelve months, resulting in a net income of $23.28 million and an EBITDA of $24.26 million. The substantial gap between revenue and net income, where profit margin reaches 24.6% while gross margin stands at 47.5%, reveals a cost structure where operating expenses are being managed efficiently relative to gross sales, although the operating margin currently registers at -250.4%. This negative operating margin suggests that fixed costs or specific operational expenditures are temporarily exceeding operating income before reaching the final net profit line. The company possesses significant financial flexibility with free cash flow of $29.07 million and total cash reserves of $154.97 million, which far exceed its total debt of $759,207. The balance sheet appears highly conservative given that the current ratio is 11.83, indicating that the company holds more than eleven times the liquidity required to cover its short-term liabilities. Furthermore, the debt-to-equity ratio of 0.38 demonstrates a low leverage profile, while the return on equity of 11.2% and return on assets of 6.4% indicate that management is generating effective returns on the capital deployed by shareholders and the asset base.

Évaluation de la valorisation

The valuation metrics for SIGA Technologies, Inc. show a trailing P/E ratio of 14.31 and a forward P/E of 3.12. The significant disparity between these two figures implies that the market expects earnings growth that would theoretically drive the valuation multiple down from the current trailing level to the projected forward level, or conversely, that current earnings are elevated relative to future expectations. The price-to-book ratio is calculated at 1.65, which indicates that the company's market capitalization trades at a 65% premium over its net asset value. Additionally, the price-to-sales ratio stands at 3.47 and the EV/EBITDA multiple is 7.17, suggesting that investors are willing to pay a premium for the company's revenue generation and earnings power relative to its enterprise value. Regarding price volatility, the stock has a 52-week high of $9.62 and a 52-week low of $4.56. The beta value of 1.06 indicates that the stock's price movements generally track with the broader market, exhibiting neither excessive volatility nor significant defensive characteristics.

Growth & Income

The financial growth metrics reveal a year-over-year revenue decline of -95.3%, while earnings growth is listed as N/A. The absence of positive earnings growth relative to the decline in revenue suggests a specific contraction in the current reporting period or a restructuring of the income statement that does not follow standard revenue scaling patterns. As the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders. Instead, the company reinvests its substantial free cash flow and cash reserves into its operations, research, and the commercialization of its lead product TPOXX. Consequently, the overall growth and income profile is characterized by a lack of current dividend income and significant negative revenue momentum, relying entirely on capital appreciation potential and the long-term value of its smallpox treatment portfolio.